

Survey on Chinese urologists of BCG utilization in Chinese NMIBC patients

First published: 10/05/2022

Last updated: 07/07/2022

Study

Planned

Administrative details

EU PAS number

EUPAS47111

Study ID

48098

DARWIN EU® study

No

Study countries

China

Study status

Planned

Research institutions and networks

Institutions

Sun Yat-Sen University

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Sun Yat-Sen Memorial Hospital

Contact details

Study institution contact

Tan Ziyin zi.yin.tan@merck.com

Study contact

zi.yin.tan@merck.com

Primary lead investigator

Huang Jian

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 08/07/2022

Study start date

Planned: 26/07/2022

Date of final study report

Planned: 01/12/2022

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

MSD (China) Holding Co., Ltd.

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Drug utilisation

Main study objective:

• To describe characteristics of Chinese NMIBC patients • To describe BCG utilization pattern in China in NMIBC treatment • To learn about factors which could impact physicians' prescribing decision and patients' choice of BCG treatment

Study Design

Non-interventional study design

Cross-sectional

Population studied

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

322

Study design details

Outcomes

1.Chinese NMIBC patients' characteristics 2.Current BCG treatment patterns and the most common one in Chinese high risk NMIBC patients' treatment 3.Factors may impact clinical decisions□ income of the family, disease stage, complicated operation, treatment frequency etc. □ in Chinese high risk NMIBC patients' treatment 4.Reasons of BCG discontinued other than disease progression

Data analysis plan

Data will be analyzed descriptively: number, rate, mean, median according to the intervention practiced and in the overall population studied.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

A survey on Chinese urologists

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No